Webinar on Ataxia-Telangiectasia Unmet Need Hosted by Quince Therapeutics
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on advancing treatments for rare diseases, has announced that it will host an investor webinar today, Friday, February 7, 2025, at 10:00 a.m. Eastern Time. This webinar will feature key opinion leader (KOL) Dr. Mary Kay Koenig from UTHealth Houston, who will provide an in-depth discussion on the unmet need in Ataxia-Telangiectasia (A-T). The event will also include an update on the company’s Phase 3 clinical trial, NEAT (Neurologic Effects of EryDex on Subjects with A-T), which aims to evaluate the neurological effects of EryDex in patients with A-T.
Quince Therapeutics has made significant progress in its clinical trials for A-T. The company disclosed that it has successfully enrolled 46 participants in its pivotal Phase 3 NEAT trial. This trial is being conducted to assess the safety and efficacy of EryDex, the company’s lead asset. EryDex is an innovative treatment, encapsulating dexamethasone sodium phosphate (DSP) in autologous red blood cells for the treatment of A-T, a rare and debilitating neurodegenerative disorder. The Phase 3 trial aims to include approximately 86 patients aged six to nine years and 20 patients aged 10 years or older.
Dr. Dirk Thye, CEO and Chief Medical Officer of Quince Therapeutics, expressed optimism about the progress of the trial. He noted that enrollment is nearing 50% completion, with 61 participants screened to date. The company expects the pace of screening and randomization to accelerate in the coming weeks due to the activation of several new sites across different geographic regions. Quince anticipates completing the enrollment by the second quarter of 2025, with topline results expected by the end of 2025. The trial, which has been granted Special Protocol Assessment (SPA) status by the U.S. Food and Drug Administration (FDA), is designed to determine the efficacy of EryDex in treating the neurological effects of A-T.
The NEAT trial is a multi-center, international, randomized, double-blind, placebo-controlled study, with participants being randomized to receive either EryDex or a placebo. The treatment involves six infusions scheduled every 21 to 30 days, and the primary efficacy endpoint will be measured by a change in the modified International Cooperative Ataxia Rating Scale (RmICARS), compared to the placebo. This endpoint is in accordance with the SPA agreement with the FDA.
In addition to the clinical trial, Quince Therapeutics has initiated an open-label extension of the study. To date, 17 participants in the U.S., U.K., and European Union have transitioned into the open-label extension phase after completing the treatment period, study assessments, and informed consent. This extension study will provide further insights into the long-term effects of EryDex.
Quince’s ongoing efforts in A-T research are aligned with the growing need for effective treatments for A-T, which is characterized by progressive neurodegeneration, immunodeficiency, and an increased risk of cancer. The disease often leads to significant disability, and current treatment options are limited to symptom management, with no disease-modifying therapies available. As Dr. Koenig will highlight in the webinar, the unmet need for effective treatments in A-T is high, making Quince’s work particularly important.
Dr. Mary Kay Koenig, a leading expert on A-T and neurodegenerative diseases, will provide an overview of the natural history of A-T, as well as the current approaches to managing symptoms in patients with the disorder. She will also discuss the competitive therapeutic landscape and Quince’s Phase 3 clinical trial of EryDex. Dr. Koenig’s clinical expertise is highly regarded, and her contributions to the field of pediatric neurodegenerative diseases, including A-T, have been instrumental in advancing research and improving patient care.
Dr. Koenig is a Professor and Associate Vice-Chair for Clinical Research at the Department of Pediatrics, Division of Child and Adolescent Neurology, at the McGovern Medical School at the University of Texas, Houston. She is also an Endowed Chair of Mitochondrial Medicine and the Director of the Center for the Treatment of Pediatric Neurodegenerative Disease. Dr. Koenig’s extensive experience and leadership in the field make her a valuable addition to Quince’s webinar, as she will share her insights on A-T and its treatment landscape.
Quince Therapeutics is also committed to advancing its clinical pipeline beyond A-T. The company’s platform focuses on utilizing a patient’s own biology to develop novel therapies for rare diseases. By leveraging innovative technologies like EryDex, Quince is working to provide patients with treatments that address the underlying causes of disease, rather than just alleviating symptoms.
To register for the webinar, investors and interested parties can visit Quince Therapeutics’ Investor Relations website. The live webcast will be available on the company’s Events page, where an archive of the presentation will be posted shortly after the event concludes.
Quince Therapeutics’ efforts to address the needs of patients with rare neurodegenerative diseases like A-T represent a significant advancement in the biotechnology field. By focusing on patient-centric solutions, such as EryDex, the company is working to transform the treatment landscape for A-T and other rare diseases.
About Quince Therapeutics
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. The company’s lead asset, EryDex, is being developed as a potential treatment for Ataxia-Telangiectasia, a rare and severe neurodegenerative disorder, through an innovative approach that encapsulates dexamethasone in autologous red blood cells.
